• The evidence base for recommendations on antivirals and other disease-modifying treatments has been reviewed and a recommendation specific to remdesivir has been added.
Following another week of continuous evidence surveillance there is still no evidence for the effectiveness for ANY treatments for COVID-19. The Taskforce has strengthened its recommendation that all experimental therapies should only be given in the context of randomised trials with appropriate ethical approval.
• A new recommendation has been added on the use of prone positioning in people who are not mechanically ventilated.
• A new recommendation has been added regarding the use of venous thromboembolism (VTE) prophylaxis in people with moderate COVID-19.
NB–The Taskforce is currently reviewing the evidence in order to make urgent recommendations on the use of high dose VTE prophylaxis in patients with severe and critical COVID-19. This is in response to emerging observational data indicating a high incidence of VTE among people with COVID-19 (including pulmonary embolism and deep vein thrombosis).
Updates to clinical flowcharts this week include:
• A dedicated flowchart for respiratory support for patients with severe to critical COVID-19
New clinical questions prioritised this week for evidence review relate to:
We continue to receive a steady stream of suggestions for priority guideline questions via the Taskforce website and broader clinical network. These are reviewed and prioritised each week via a formal process overseen by our evidence team, expert panels and Guidelines Leadership Group.
A summary of all of the topic areas for which we have received suggested questions is provided below.
Questions related to infection prevention and control/ (IPC) and personal protective equipment (PPE).
A large number of questions related to infection prevention and control (IPC) and the use of personal protective equipment (PPE) have been received and are clearly important issues for clinicians.While IPC-related guidance is beyond the initial scope of the Taskforce (to provide recommendations on clinical care), we have established representation from the Infection Control Expert Group (ICEG) which develops IPC and PPE guidance for the Australian Health Protection Principal Committee (AHPPC).
Current guidance developed by ICEG is available at https://www.health.gov.au/committees-and-groups/infection-control-expert-group-iceg
We are currently working to explore ways we can provide support to ICEG to understand and address the priority questions being brought to the Taskforce.
Please encourage your clinical colleagues to visit the Taskforce website to provide their valuable feedback and insights www.clinicalevidence.net.au